Skip to main content
Have a personal or library account? Click to login
Effects of Cyp2c19 and P2y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel After Acute Ischemic Cerebrovascular Disease Cover

Effects of Cyp2c19 and P2y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel After Acute Ischemic Cerebrovascular Disease

Balkan Journal of Medical Genetics
Volume 17 (2014): Issue 2 (December 2014)
By: ,  ,   and    
Open Access
|Apr 2015
References

References

  1. 1. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al.; American Heart Association; American Stroke Association. Update to the AHA/ ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008; 39(5): 1647-1652.
    Open DOISearch in Google Scholar
  2. 2. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011; 76(6 Suppl): S85-S90.
    Open DOISearch in Google Scholar
  3. 3. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, et al. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Int J Cardiol. 2013; 168(2): 1594-1596.
    Open DOISearch in Google Scholar
  4. 4. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7): 1648-1652
    Open DOISearch in Google Scholar
  5. 5. Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, et al. Feasibility of a microarraybased point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int. 2013; 2013: 154073. doi: 10.1155/2013/154073.
    Open DOISearch in Google Scholar
  6. 6. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Gene: CYP2C19. Available from: http://www.pharmgkb.org/gene/PA124. Accessed November 10 2014.
    Search in Google Scholar
  7. 7. Scott SA, Sangkuhl K, Gardner EE, Stein CM. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Parmacol Therapeut. 2011; 90(2): 328-332.
    Open DOISearch in Google Scholar
  8. 8. Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb. 2014; 21(1): 64-76.
    Open DOISearch in Google Scholar
  9. 9. Kim KA, Song WG, Lee HM, Joo HJ, Park JY. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Thromb Res. 2013; 132(2): 221-226.
    Open DOISearch in Google Scholar
  10. 10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84(5): 891-896.
    Open DOISearch in Google Scholar
  11. 11. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994; 269(2): 772-777.
    Search in Google Scholar
  12. 12. Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999; 19(4): 1142-1147.
    Open DOISearch in Google Scholar
  13. 13. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thromb Res. 2011; 128(1): 47-53
    Open DOISearch in Google Scholar
  14. 14. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005; 36(7): 1394-1399.
    Open DOISearch in Google Scholar
  15. 15. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013; 106(10): 517-527.
    Open DOISearch in Google Scholar
  16. 16. Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, et al. Effects of coexisting polymorphisms of CYP2 C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl). 2013; 126(6): 1069-1075.
    Search in Google Scholar
  17. 17. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996; 348 (9038): 1329-1339.
    Open DOISearch in Google Scholar
  18. 18. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003; 91(9): 1123-1125.
    Open DOISearch in Google Scholar
  19. 19. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23): 2908-2913.
    Open DOISearch in Google Scholar
  20. 20. Spokoyny I, Barazangi N, Jaramillo V, Rose J, Chen C, Wong C, et al. Reduced clopidogrel metabolism in a multiethnic population: Prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis. 2014; 23(4): 694-698.
    Open DOISearch in Google Scholar
  21. 21. Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: Are we there yet? Stroke. 2010; 41(12): 2997-3002.
    Open DOISearch in Google Scholar
  22. 22. US Food and Drug Administration. Clopidogrel black box warning. Available from: http:// www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm. Accessed November 10, 2014.
    Search in Google Scholar
  23. 23. Terpening C. Clopidogrel: A pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol. 2010; 4(1): 117-128.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/bjmg-2014-0072 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Journal RSS Feed
Language: English
Page range: 37 - 41
Published on: Apr 10, 2015
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Keywords:
Ischemic cerebrovascular disease (ICVD),
clopidogrel,
CYP2C19 and P2Y12 gene polymorphisms
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2015 H. M. Sen, F. Silan, Y. Degirmenci, Ozisik H. I. Kamaran, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 17 (2014): Issue 2 (December 2014)
Previous article
Next article